SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the company will present at the 25th Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2013 at 4:00 PM Eastern Time in New York.
A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.mirati.com. Replays of the presentation will be available at the same location for 30 days following the conference.
About Mirati Therapeutics Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations. Mirati's approach combines the three most important factors in oncology drug development - drug candidates with complementary and compelling targets, creative and agile clinical development, and a highly accomplished precision medicine leadership team. The Mirati team is using its proven blueprint for developing targeted oncology medicines to advance and maximize the value of its pipeline of drug candidates, including MGCD265 and MGCD516, which are orally bioavailable, multi-targeted kinase inhibitors with distinct target profiles, and mocetinostat, an orally bio-available, spectrum-selective histone deacetylase inibitor. More information is available at www.mirati.com.
SOURCE Mirati Therapeutics, Inc.